Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Low-Dose Computed Tomography (CT) Lung Screening Programs Market Growth Potential: How Will Market Size Shift Through 2030?
The low-dose computed tomography (CT) lung screening programs market has witnessed rapid growth in recent years. Its size is expected to increase from $1.66 billion in 2025 to $1.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This historical expansion can be attributed to the rising prevalence of lung cancer cases, increasing awareness about early cancer detection, growing recommendations from clinical guidelines, the expansion of hospital-based screening infrastructure, and increasing healthcare reimbursement support.
The low-dose computed tomography (CT) lung screening programs market is poised for significant expansion in the coming years. This market is projected to reach $2.78 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth over the forecast period include the increasing integration of AI in CT screening, the broadening of precision oncology efforts, a surge in investments in mobile healthcare models, the greater incorporation of telehealth for consultations, and the development of more public-private collaborations in preventive health. Key developments anticipated during this timeframe involve an increase in government-backed lung cancer screening programs, a higher uptake of mobile screening facilities in remote regions, the enhanced bundling of smoking cessation support with screening, a greater focus on identifying patients based on risk, and the broadening of services for radiology interpretation and subsequent monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Low-Dose Computed Tomography (CT) Lung Screening Programs Market Growth Drivers: What’s Behind The Acceleration?
The increasing prevalence of lung cancer is a significant factor propelling the expansion of the low-dose computed tomography (CT) lung screening programs market. This disease, a malignancy developing in lung tissue, involves the uncontrolled proliferation of abnormal cells, frequently showing no symptoms until its later stages. Its rising occurrence is largely attributable to ongoing tobacco consumption, supplemented by other risk factors such as exposure to environmental pollutants and workplace carcinogens. Low-dose CT lung screening programs are vital for managing lung cancer, facilitating the early identification of tumors, especially in high-risk individuals like long-term smokers. As an illustration, the Australian Government reported in February 2026 that approximately 15,108 new instances of lung cancer were identified in 2025, constituting 9.0% of all new cancer diagnoses. Consequently, the growing impact of lung cancer is fostering the development of the low-dose computed tomography (CT) lung screening programs market.
Low-Dose Computed Tomography (CT) Lung Screening Programs Market Segment Breakdown: Which Categories Lead On Revenue?
The low-dose computed tomography (CT) lung screening programs market covered in this report is segmented –
1) By Type: Hospital-Based, Independent Imaging Centers, Mobile Screening Units
2) By Service: Screening Services, Diagnostic Follow-Up Services, Radiology Interpretation Services, Patient Identification And Risk Assessment Services, Program Management Services, Telehealth And Remote Consultation Services
3) By Technology: Standard Low-Dose CT Screening, AI-Assisted/Computer-Aided Detection (CAD) Screening, Integrated Smoking Cessation And Screening Programs
4) By Application: Early Detection, Risk Assessment, Follow-Up Monitoring
5) By End User: Hospitals And Multi-Specialty Clinics, Standalone Diagnostic Imaging Centers, Mobile Screening Service Providers, Government And Public Health Agencies, Private Healthcare Networks And Insurance Providers, Employer And Corporate Wellness Programs, Academic And Research Institutions, Community Health Centers
Subsegments:
1) By Hospital-Based: Outpatient Department, Inpatient Department, Radiology Department
2) By Independent Imaging Centers: Standalone Imaging Clinics, Diagnostic Centers, Specialized Lung Screening Centers
3) By Mobile Screening Units: Bus-Based Screening Units, Van-Based Screening Units, Temporary Pop-Up Screening Units
Low-Dose Computed Tomography (CT) Lung Screening Programs Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the low-dose computed tomography (CT) lung screening programs market are concentrating on developing advanced solutions, notably artificial intelligence (AI)–assisted nodule detection, to improve early cancer discovery, enhance diagnostic precision, and streamline patient management. AI-assisted nodule detection specifically utilizes machine-learning algorithms within lung screening programs to automatically identify, characterize, and prioritize pulmonary nodules found on low-dose CT scans, enabling prompt follow-up and intervention. As an illustration, in December 2025, Emory Healthcare, a US-based health system, unveiled the Emory Healthcare Lung Screening and Nodule Program, which incorporates low-dose CT screening with AI-enhanced imaging technology. This program supports multidisciplinary care by integrating advanced diagnostic and treatment options, including robot-assisted bronchoscopy, minimally invasive lung cancer surgery, and coordinated care navigation, thereby facilitating early diagnosis, personalized treatment planning, and improved patient outcomes across several metro Atlanta locations.
Low-Dose Computed Tomography (CT) Lung Screening Programs Market Key Players Shaping Industry Direction
Major companies operating in the low-dose computed tomography (CT) lung screening programs market are Hitachi Medical Systems America Inc., Medtronic plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Inc., Mayo Clinic, Columbia University Herbert Irving Comprehensive Cancer Center, Duke University Health System, Emory Healthcare, Canon Medical Systems Corporation, RadNet Inc., University of Tennessee Medical Center, McLeod Health, Holy Cross Health, Lima Memorial Health System, Memorial Sloan Kettering Cancer Center, Independence Health System, Weill Cornell Medicine & NewYork-Presbyterian Mobile Unit, Optellum Ltd., 4DMedical Pty Ltd.
View The Full Low-Dose Computed Tomography (CT) Lung Screening Programs Market Report:
Low-Dose Computed Tomography (CT) Lung Screening Programs Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the low-dose computed tomography (CT) lung screening programs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-dose computed tomography (CT) lung screening programs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

